Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 82


Less sensitive HIV-1 enzyme immunoassay as an adjuvant method for monitoring patients receiving antiretroviral therapy.

Cimerman S, Sucupira MC, Lewi DS, Diaz RS.

AIDS Patient Care STDS. 2007 Feb;21(2):100-5.


Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP.

AIDS. 2008 Jan 30;22(3):385-93. doi: 10.1097/QAD.0b013e3282f3f16d.


Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.


Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.

Bergroth T, Ekici H, Gisslén M, Loes SK, Goh LE, Freedman A, Lampe F, Johnson MA, Sönnerborg A.

J Med Virol. 2009 Jan;81(1):1-8. doi: 10.1002/jmv.21363.


Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.

Spire B, Marcellin F, Cohen-Codar I, Flandre P, Boue F, Dellamonica P, Raffi F, Norton M, Van Philippe N, Delfraissy JF.

Antivir Ther. 2008;13(4):591-9.


Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.


Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.

Günthard HF, Havlir DV, Fiscus S, Zhang ZQ, Eron J, Mellors J, Gulick R, Frost SD, Brown AJ, Schleif W, Valentine F, Jonas L, Meibohm A, Ignacio CC, Isaacs R, Gamagami R, Emini E, Haase A, Richman DD, Wong JK.

J Infect Dis. 2001 May 1;183(9):1318-27. Epub 2001 Apr 10.


Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.

Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, Essajee S.

Pediatrics. 2007 Oct;120(4):e856-61. Epub 2007 Sep 10.


High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.

Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM.

J Antimicrob Chemother. 2009 Feb;63(2):380-8. doi: 10.1093/jac/dkn471. Epub 2008 Nov 25.


Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.

Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV.

J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):441-9.


Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.

van Vonderen MG, van Agtmael MA, Hassink EA, Milinkovic A, Brinkman K, Geerlings SE, Ristola M, van Eeden A, Danner SA, Reiss P; MEDICLAS study group.

PLoS One. 2009 May 21;4(5):e5647. doi: 10.1371/journal.pone.0005647.


Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.

Ghosn J, Chaix ML, Peytavin G, Bresson JL, Galimand J, Girard PM, Raffi F, Cohen-Codar I, Delfraissy JF, Rouzioux C.

J Antimicrob Chemother. 2008 Jun;61(6):1344-7. doi: 10.1093/jac/dkn098. Epub 2008 Mar 13.


Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.

Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks CB, Klein CE, Chiu YL, King MS, Bernstein BM.

AIDS Res Hum Retroviruses. 2009 Mar;25(3):269-75. doi: 10.1089/aid.2008.0217.


Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.

Peuchant O, Thiébaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, Morlat P, Dabis F, Fleury H, Masquelier B; ANRS CO3 Aquitaine Cohort.

AIDS. 2008 Jul 31;22(12):1417-23. doi: 10.1097/QAD.0b013e3283034953.


Persistence of lamivudine-sensitive HIV-1 quasispecies in the presence of lamivudine in vitro and in vivo.

Allers K, Knoepfel SA, Rauch P, Walter H, Opravil M, Fischer M, Günthard HF, Metzner KJ.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):377-85.


Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group.

Clin Infect Dis. 2007 Aug 1;45(3):381-90. Epub 2007 Jun 26.


Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania.

Johannessen A, Garrido C, Zahonero N, Sandvik L, Naman E, Kivuyo SL, Kasubi MJ, Gundersen SG, Bruun JN, de Mendoza C.

Clin Infect Dis. 2009 Sep 15;49(6):976-81. doi: 10.1086/605502.


Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.

Chalermchockcharoenkit A, Culnane M, Chotpitayasunondh T, Vanprapa N, Leelawiwat W, Mock PA, Asavapiriyanont S, Teeraratkul A, McConnell MS, McNicholl JM, Tappero JW.

Clin Infect Dis. 2009 Jul 15;49(2):299-305. doi: 10.1086/599612.


Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.

Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.

Antivir Ther. 2009;14(3):339-47.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk